A family's guide to specialty drug access abroad.

This guide is written for families navigating cross-border specialty drug access for the first time, without assuming any background in pharmaceutical regulation, supply chain logistics, or the vocabulary of international pharmacy. It is deliberately long, because the subject is genuinely complicated, and short guides that pretend otherwise usually leave families with a false sense of certainty and an incomplete map. The material below is roughly the same material we would cover in several conversations over several weeks; a family is welcome to read it in one sitting or in pieces, whichever serves.

What a named-patient program actually is

A named-patient program is a specific regulatory pathway that permits a medicine to be imported into a country for a single, identified patient, under the authorization of that country's health authority, for an indication the treating physician has determined is medically appropriate. The words matter. "Named patient" means the authorization is tied to one individual, not to a market; the medicine does not become generally available in the destination country as a result. "Program" means there is a defined process the authorization follows, with specific documents, specific sign-offs, and specific timelines. The pathway exists in most of the countries we serve because regulators recognize that the domestic registration and reimbursement systems cannot be expected to cover every therapy for every patient in every country, and that a safety-valve mechanism for individual medical need is appropriate.

In plain English, the NPP is the way a patient in the United Arab Emirates, Saudi Arabia, India, Pakistan, or any of the other countries in our coverage map can legally obtain a specific specialty therapy that is not available in their country, using a process that their country's regulator recognizes. It is not a loophole; it is a deliberate regulatory feature.

Where the medicine comes from

In our model, the medicine comes from the United States. We source every unit through DSCSA-serialized US specialty wholesale channels, and we dispense through Altima Care, a US-licensed specialty wholesaler. The technical acronym DSCSA refers to the US federal Drug Supply Chain Security Act, which requires that specialty medicine in the US carry a serial number at package level and that every transaction in the chain be documented. The effect, for a family, is that the unit of medicine your relative receives can be traced from the manufacturer's fill line to the patient, and that the documentation for that trace travels with the shipment.

We have written in more detail about sourcing elsewhere on the site, and the technical account is on the how we source page. For most families, the short version is sufficient: the medicine is manufacturer-authorized, it is not a gray-market unit, it has not been repackaged in transit, and the documentation is continuous.

The role of the local prescriber

The treating physician at home is the center of the case, and a good cross-border coordinator keeps it that way. The prescriber identifies the therapy, writes the prescription, signs the medical-necessity letter that supports the named-patient application, administers or oversees the administration of the therapy, and handles the follow-up. Our role is to be the infrastructure between that prescriber and a US-anchored supply chain; we do not prescribe, we do not substitute for the prescriber, and we do not insert ourselves into the clinical relationship.

If a coordinator offers to arrange a therapy without the treating physician's engagement, that is a warning sign. The treating physician's prescription and medical-necessity letter are the foundation of the regulatory case at destination, and no legitimate coordinator can manufacture those documents independently. A family whose prescriber is not yet willing to write the paperwork should have the conversation with the prescriber first, not with a coordinator.

Questions to bring to the local prescriber

Before starting a conversation with a cross-border coordinator, a family can usefully bring a short list of questions to the treating prescriber. Is the therapy you are recommending currently the therapy you would write if the patient were in a country where it were straightforwardly available? If a locally-available alternative exists, what is the clinical reason for preferring the cross-border therapy? Are you willing to sign a prescription and a medical-necessity letter that the destination country's health authority will review? Are you willing to remain the clinical contact through administration, follow-up, and any adverse-event reporting? Do you have specific concerns about the chain-of-custody or the supply chain that we should discuss before engaging a coordinator?

The answers tell the family and the family's advisers a great deal about how the case is likely to move. A prescriber who answers these questions clearly and affirmatively is a prescriber with whom the cross-border path will go well. A prescriber who is uncertain about any of the questions is signaling that more work is needed before a cross-border engagement begins, and that work is the right work to do first.

The timeline to expect

A straightforward specialty case, from the moment the family contacts us to the moment the therapy arrives at the receiving institution, typically takes two to four weeks. More complex cases, involving ultra-cold or cryogenic logistics, or destinations where the named-patient pathway requires additional application steps, can take six to ten weeks. Cases that require a fresh named-patient application for a drug-indication combination that has not previously moved into the destination country can take longer.

The timeline shape is typically: one to two days for intake and feasibility; three to seven days for clinical review once documents are in hand; three to seven days, sometimes in parallel with clinical review, for regulatory review and documentation assembly; three to ten days for sourcing, dispensing, and logistics depending on the product and the route; one to three days for customs clearance and destination-side receipt. The phase that most commonly extends the timeline is regulatory review, because the destination-country authority is not on our schedule.

A family should ask the coordinator to quote a specific window rather than a best-case number, and should expect the coordinator to communicate promptly if the window slides. What a family should not accept is a coordinator that quotes aggressively and then manages the slippage silently.

The paperwork

There is more paperwork in a named-patient case than in a domestic prescription, and there is less than a family often fears. The specific documents vary by destination, but the core set is stable. The prescription, written in a form the destination country accepts. The medical-necessity letter, signed by the treating physician. The patient consent, signed by the patient or a legally authorized representative. The import authorization, issued by the destination country's health authority; we prepare and file this. The manufacturer's product documentation, which moves with the shipment. The chain-of-custody records from the US supply chain, which also move with the shipment. Most of the paperwork burden sits with us and the treating physician; the family's direct paperwork burden is typically limited to the consent and to sharing any medical-record elements the treating physician has not already supplied.

We provide a medical-necessity letter template for prescribers and a named-patient consent template for patients to adapt; a family is welcome to share those templates with the treating prescriber directly. Prescribers who have not worked cross-border before often appreciate a starting document rather than drafting from blank paper.

The cost conversation

Cross-border specialty therapy is expensive, and the honest conversation about cost is best had early. The total cost of a coordinated case includes the drug itself, the import duty and freight to the destination country, the cold-chain logistics for the temperature class the product requires, and the coordinator's fee. A thoughtful coordinator will show each line item separately on the quote, rather than present a bundled figure that obscures where the cost actually sits. Families comparing coordinators should ask each for a line-item quote and compare like against like.

We have published indicative ranges by therapy modality on the what to expect on cost page. Those ranges are a starting orientation, not a quote; an actual quote is case-specific and is issued only after we have reviewed the prescription, the destination, and the logistics profile. For the structural view of how we think about pricing, the pricing principles page is the source.

A family should expect to prepay. Reserve Meds is cash-pay and does not bill insurance; the therapies we coordinate move on prepayment, with clearly disclosed refund terms written into the engagement letter. Families should not expect a coordinator in this space to finance the drug cost; the industry does not generally work that way, for reasons that relate to how specialty manufacturers price their products.

The emotional pacing

Specialty cases take weeks, and the weeks are usually weeks in which someone in the family is waiting for a treatment they hope will help. The waiting is hard, and the quality of the waiting is meaningfully shaped by the quality of the communication from the coordinator. A good coordinator communicates at stage transitions rather than at end-of-project, and uses email or a dedicated channel rather than noisy consumer messaging apps. A family is entitled to ask for a specific communication cadence; we offer a short stage-transition note by default, and we adjust if a family prefers more or less.

Families sometimes find that the cross-border process becomes a container for the broader stress of the diagnosis. It is worth noticing that when it happens, because conflating the two can make both harder to manage. The cross-border process is a logistics and regulatory exercise with specific milestones and specific paperwork; the diagnosis is a separate, more consuming reality that moves at its own pace. Keeping them conceptually separate, at least for the purpose of managing each, often helps families get through both in better shape.

What we expect of ourselves, plainly

We expect of ourselves that we return a candid answer to an inquiry within one business day, that we decline cases honestly and quickly where a decline is the right call, that we quote on a line-item basis, that we communicate at stage transitions rather than at the end, that we source through the DSCSA chain and dispense through Altima Care every time, and that we remain engaged through the first follow-up cycle after administration. Where any of those commitments breaks, we want the family to tell us. Our complaints channel is [email protected] and complaints are answered within five business days.

First practical step for a family

The first practical step, for a family who has read this far and wants to explore whether we can help, is short. Confirm that the treating physician is engaged and willing to write the paperwork a named-patient case requires. Gather what the physician has already written. Use the self-screening walkthrough to confirm that our model fits the situation. Then send a short note to the consultation desk or use the consultation form on the site. We will return an initial feasibility signal within one business day. If we cannot help, we will say so and point toward a better path. If we can, we will describe what the next steps look like in specific terms. There is no commitment at intake, and there is no fee for the initial review.

Reviewed 2026-04-22 by Reserve Meds’s AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.